Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel Free HALO Stock Alerts

Halozyme Therapeutics (HALO) Financials

Halozyme Therapeutics logo
$67.44 +0.32 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$67.31 -0.13 (-0.19%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Halozyme Therapeutics

Annual Income Statements for Halozyme Therapeutics

This table shows Halozyme Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -32 -103 63 -80 -72 129 403 202 282 444 317
Consolidated Net Income / (Loss)		 -32 -103 63 -80 -72 129 403 202 282 444 317
Net Income / (Loss) Continuing Operations		 -32 -103 63 -80 -72 129 403 202 282 444 317
Total Pre-Tax Income 		-32 -102 62 -80 -72 129 249 249 348 557 467
Total Operating Income		 -27 -83 81 -69 -68 144 276 268 338 551 469
Total Gross Profit		 106 113 285 142 150 224 362 521 637 856 1,168
Total Revenue		 135 147 317 152 196 268 443 660 829 1,015 1,397
Operating Revenue		 135 147 317 152 196 268 443 660 829 1,015 1,397
Total Cost of Revenue		 29 33 31 10 46 43 81 139 192 159 229
Operating Cost of Revenue		 29 33 31 10 46 43 81 139 192 159 229
Total Operating Expenses		 133 197 204 211 218 80 86 253 299 304 699
Selling, General & Admin Expense		 40 46 54 61 77 46 50 144 149 154 207
Research & Development Expense		 93 151 151 150 141 34 36 67 76 79 366
Amortization Expense		 - - - - - 0.00 0.00 43 74 71 77
Impairment Charge		 - - - - - - - - - - 49
Total Other Income / (Expense), net		 -4.78 -19 -19 -10 -4.64 -15 -27 -19 11 5.66 -2.13
Interest Expense		 5.20 20 22 18 12 20 28 20 19 18 24
Interest & Investment Income		 - - - - - - 0.00 0.00 13 0.00 0.00
Other Income / (Expense), net		 0.42 1.33 2.59 7.58 6.99 5.43 1.10 1.05 16 24 21
Income Tax Expense		 0.00 1.16 -1.36 0.54 -0.01 0.22 -154 47 67 113 150
Basic Earnings per Share		 ($0.25) ($0.81) $0.46 ($0.56) ($0.50) $0.95 $2.86 $1.48 $2.13 $3.50 $2.64
Weighted Average Basic Shares Outstanding		 126.70M 127.96M 136.42M 143.60M 144.33M 136.21M 140.65M 136.84M 131.93M 126.83M 119.84M
Diluted Earnings per Share		 ($0.25) ($0.81) $0.45 ($0.56) ($0.50) $0.91 $2.74 $1.44 $2.10 $3.43 $2.56
Weighted Average Diluted Shares Outstanding		 126.70M 127.96M 139.07M 143.60M 144.33M 141.46M 146.80M 140.61M 134.20M 129.42M 123.90M
Weighted Average Basic & Diluted Shares Outstanding		 126.70M 127.20M 0.00 143.60M 144.33M 135.28M 137.70M 135.37M 126.82M 123.15M 118.02M

Quarterly Income Statements for Halozyme Therapeutics

This table shows Halozyme Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 82 85 77 93 137 137 118 165 175 -142 150
Consolidated Net Income / (Loss)		 82 85 77 93 137 137 118 165 175 -142 150
Net Income / (Loss) Continuing Operations		 82 85 77 93 137 137 118 165 175 -142 150
Total Pre-Tax Income 		102 101 96 118 165 178 144 205 219 -101 180
Total Operating Income		 88 101 96 117 163 176 142 202 218 -93 185
Total Gross Profit		 161 178 168 192 241 256 216 279 299 373 297
Total Revenue		 216 230 196 231 290 298 265 326 354 452 377
Operating Revenue		 216 230 196 231 290 298 265 326 354 452 377
Total Cost of Revenue		 55 52 28 40 49 42 48 46 55 79 79
Operating Cost of Revenue		 55 52 28 40 49 42 48 46 55 79 79
Total Operating Expenses		 73 77 72 75 77 80 75 77 81 466 113
Selling, General & Admin Expense		 35 38 35 36 41 42 42 42 46 77 58
Research & Development Expense		 17 21 19 21 18 20 15 18 17 317 26
Amortization Expense		 20 18 18 18 18 18 18 18 18 23 30
Total Other Income / (Expense), net		 13 0.14 0.49 0.51 1.95 2.71 2.29 2.50 1.04 -7.96 -4.19
Interest Expense		 4.51 5.22 4.51 4.52 4.52 4.54 4.53 4.39 4.30 10 5.51
Other Income / (Expense), net		 4.79 5.36 4.99 5.03 6.47 7.25 6.82 6.89 5.33 2.43 1.32
Income Tax Expense		 20 16 19 24 28 41 26 40 44 41 30
Basic Earnings per Share		 $0.62 $0.65 $0.61 $0.73 $1.08 $1.08 $0.96 $1.36 $1.49 ($1.17) $1.27
Weighted Average Basic Shares Outstanding		 131.97M 131.93M 126.94M 127.12M 126.85M 126.83M 123.22M 121.34M 117.22M 119.84M 118.14M
Diluted Earnings per Share		 $0.61 $0.64 $0.60 $0.72 $1.05 $1.06 $0.93 $1.33 $1.43 ($1.13) $1.22
Weighted Average Diluted Shares Outstanding		 134.08M 134.20M 128.89M 129.22M 130.13M 129.42M 126.64M 124.16M 122.33M 123.90M 122.88M
Weighted Average Basic & Diluted Shares Outstanding		 132.10M 126.82M 127.27M 126.68M 127.23M 123.15M 123.22M 116.97M 117.60M 118.02M 118.61M

Annual Cash Flow Statements for Halozyme Therapeutics

This table details how cash moves in and out of Halozyme Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -18 23 102 -111 62 28 -29 115 -116 -2.52 21
Net Cash From Operating Activities		 -37 -50 134 -50 -85 55 299 240 389 479 652
Net Cash From Continuing Operating Activities		 -37 -50 134 -49 -85 55 299 240 389 479 652
Net Income / (Loss) Continuing Operations		 -32 -103 63 -80 -72 129 403 202 282 444 317
Consolidated Net Income / (Loss)		 -32 -103 63 -80 -72 129 403 202 282 444 317
Depreciation Expense		 1.68 2.41 2.16 2.39 4.07 3.28 3.00 6.49 11 10 11
Amortization Expense		 1.24 16 1.46 -1.55 0.02 15 5.90 52 75 67 81
Non-Cash Adjustments To Reconcile Net Income		 22 26 31 39 33 12 40 26 25 46 394
Changes in Operating Assets and Liabilities, net		 -30 8.38 37 -8.71 -51 -104 -152 -46 -4.17 -89 -152
Net Cash From Investing Activities		 5.89 -77 -164 2.49 -5.55 78 -406 -487 -97 -263 -546
Net Cash From Continuing Investing Activities		 5.89 -77 -164 2.49 -5.55 78 -406 -487 -97 -263 -546
Purchase of Property, Plant & Equipment		 -2.36 -3.14 -1.54 -4.66 -4.04 -2.50 -1.46 -4.81 -15 -11 -6.97
Acquisitions		 - - - - - 0.00 0.00 -999 0.00 0.00 -1,014
Purchase of Investments		 -71 -155 -398 -311 -390 -226 -653 -255 -293 -648 -247
Sale and/or Maturity of Investments		 80 82 236 318 388 306 248 746 211 396 722
Net Cash From Financing Activities		 13 151 132 -64 153 -106 78 362 -408 -219 -85
Net Cash From Continuing Financing Activities		 13 151 132 -64 153 -106 78 362 -408 -219 -85
Repayment of Debt		 0.00 -54 -16 -78 -108 -20 -369 -455 -13 0.00 -1,018
Repurchase of Common Equity		 - - 0.00 0.00 -200 -150 -350 -200 -402 -250 -342
Issuance of Debt		 0.00 203 0.00 0.00 447 0.00 785 1,072 0.00 0.00 1,470
Issuance of Common Equity		 13 1.87 148 14 14 63 13 14 7.88 31 22
Other Financing Activities, net		 - - - - - 0.00 0.00 -69 0.00 0.00 -216
Cash Interest Paid		 3.78 3.89 20 17 9.03 6.53 3.30 6.11 11 11 11
Cash Income Taxes Paid		 0.00 1.44 3.02 0.22 0.19 0.18 -0.38 16 32 81 135

Quarterly Cash Flow Statements for Halozyme Therapeutics

This table details how cash moves in and out of Halozyme Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 53 -156 46 23 -34 -38 60 -114 358 -283 176
Net Cash From Operating Activities		 132 102 129 56 115 178 154 100 179 219 180
Net Cash From Continuing Operating Activities		 132 102 129 56 115 178 154 100 179 219 180
Net Income / (Loss) Continuing Operations		 82 85 77 93 137 137 118 165 175 -142 150
Consolidated Net Income / (Loss)		 82 85 77 93 137 137 118 165 175 -142 150
Depreciation Expense		 2.74 2.93 2.44 2.57 2.60 2.65 2.69 2.74 2.66 3.30 4.22
Amortization Expense		 21 17 17 17 16 17 18 18 19 25 32
Non-Cash Adjustments To Reconcile Net Income		 -4.63 14 10 11 13 12 11 12 12 358 17
Changes in Operating Assets and Liabilities, net		 32 -17 23 -68 -54 10 4.61 -99 -31 -26 -23
Net Cash From Investing Activities		 -83 -8.29 -83 -42 -167 29 -90 85 202 -742 -2.88
Net Cash From Continuing Investing Activities		 -83 -8.29 -83 -42 -167 29 -90 85 202 -742 -2.88
Purchase of Property, Plant & Equipment		 -2.94 -2.60 -3.55 -2.58 -1.52 -3.05 -0.95 -1.56 -3.03 -1.43 -3.74
Purchase of Investments		 -162 -21 -199 -93 -304 -51 -140 -103 -4.96 - -8.85
Divestitures		 - - - - - - 0.00 - - - 0.71
Sale and/or Maturity of Investments		 81 16 120 54 138 84 50 189 210 273 9.00
Net Cash From Financing Activities		 4.10 -250 -0.49 9.48 19 -246 -3.32 -299 -22 240 -1.61
Net Cash From Continuing Financing Activities		 4.10 -250 -0.49 9.48 19 -246 -3.32 -299 -22 240 -1.61
Other Financing Activities, net		 - - -0.49 - - - -3.32 - - - -1.61

Annual Balance Sheets for Halozyme Therapeutics

This table presents Halozyme Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 182 262 520 440 566 580 1,104 1,842 1,733 2,063 2,525
Total Current Assets		 172 257 510 428 543 555 926 739 746 1,085 825
Cash & Equivalents		 43 67 169 58 120 148 119 234 118 116 134
Short-Term Investments		 65 138 300 297 301 220 622 129 218 480 9.00
Accounts Receivable		 32 16 22 30 59 98 91 231 234 308 441
Inventories, net		 9.49 15 5.15 23 29 61 54 100 128 142 176
Prepaid Expenses		 22 21 14 21 33 28 40 45 49 39 65
Plant, Property, & Equipment, net		 3.94 4.26 3.52 7.47 11 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 6.07 0.72 6.05 4.93 12 25 178 1,102 987 978 1,700
Goodwill		 - - - - - - 0.00 409 417 417 580
Intangible Assets		 - - - - - - 0.00 547 473 402 981
Other Noncurrent Operating Assets		 5.57 0.22 5.55 4.43 11 25 22 102 93 156 136
Other Noncurrent Nonoperating Assets		 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 - 0.00 2.60
Total Liabilities & Shareholders' Equity		 182 262 520 440 566 580 1,104 1,842 1,733 2,063 2,525
Total Liabilities		 139 294 312 191 474 429 907 1,672 1,649 1,700 2,477
Total Current Liabilities		 62 55 131 149 86 421 117 131 112 139 177
Short-Term Debt		 22 17 77 92 20 397 89 13 - - 0.00
Accounts Payable		 4.50 3.58 7.95 4.08 6.43 1.93 1.54 18 12 10 21
Accrued Expenses		 27 29 40 50 56 20 24 100 101 129 156
Total Noncurrent Liabilities		 76 239 180 42 388 7.49 790 1,541 1,537 1,561 2,299
Long-Term Debt		 28 199 125 35 383 0.00 787 1,493 1,499 1,506 2,143
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 43
Other Noncurrent Operating Liabilities		 4.44 0.36 0.81 2.12 4.18 3.47 0.54 48 38 55 114
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 43 -32 208 249 92 151 197 170 84 364 49
Total Preferred & Common Equity		 43 -32 208 249 92 151 197 170 84 364 49
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 43 -32 208 249 92 151 197 170 84 364 49
Common Stock		 526 553 731 781 695 626 256 28 2.54 0.12 12
Retained Earnings		 -483 -585 -522 -531 -604 -475 -59 143 91 360 55
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.01 -0.45 -0.28 0.24 0.02 -0.62 -0.92 -9.28 3.83 -18

Quarterly Balance Sheets for Halozyme Therapeutics

This table presents Halozyme Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,865 1,699 1,810 1,893 1,842 1,969 2,118 2,197 2,054 2,221 2,673
Total Current Assets		 653 615 766 879 874 988 1,127 1,262 1,123 1,329 1,003
Cash & Equivalents		 147 96 221 274 165 188 154 176 62 420 310
Short-Term Investments		 118 179 127 209 299 341 512 572 486 282 8.87
Accounts Receivable		 233 195 246 217 196 215 286 305 316 346 458
Inventories, net		 103 108 132 129 169 159 131 165 182 186 155
Prepaid Expenses		 51 37 39 49 46 85 44 45 77 95 71
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 78 0.00 0.00 73 0.00 0.00 82
Total Noncurrent Assets		 1,211 1,084 1,045 1,014 890 982 991 862 931 892 1,587
Goodwill		 199 416 417 417 417 417 417 417 417 417 582
Intangible Assets		 949 529 511 491 455 437 420 384 366 349 952
Other Noncurrent Operating Assets		 62 103 93 93 17 127 155 56 128 127 51
Other Noncurrent Nonoperating Assets		 0.50 0.50 0.00 0.00 - - - - - - 2.26
Total Liabilities & Shareholders' Equity		 1,865 1,699 1,810 1,893 1,842 1,969 2,118 2,197 2,054 2,221 2,673
Total Liabilities		 1,768 1,634 1,659 1,643 1,664 1,680 1,665 1,714 1,721 1,717 2,453
Total Current Liabilities		 109 92 116 115 132 133 109 150 134 837 363
Short-Term Debt		 13 0.00 0.00 0.00 - - - - - 711 209
Accounts Payable		 18 8.70 10 19 13 15 12 20 19 15 14
Accrued Expenses		 74 80 105 95 118 118 96 130 116 111 140
Total Noncurrent Liabilities		 1,658 1,542 1,543 1,528 1,532 1,547 1,557 1,564 1,587 880 2,090
Long-Term Debt		 1,491 1,494 1,496 1,498 1,501 1,503 1,504 1,507 1,509 800 1,936
Noncurrent Deferred & Payable Income Tax Liabilities		 29 - - - - 14 12 - - 8.22 48
Other Noncurrent Operating Liabilities		 135 45 45 28 31 31 40 56 78 72 106
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 97 66 151 249 178 289 453 482 333 504 220
Total Preferred & Common Equity		 97 66 151 249 178 289 453 482 333 504 220
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 97 66 151 249 178 289 453 482 333 504 220
Common Stock		 13 0.13 12 26 12 31 62 7.72 0.12 24 28
Retained Earnings		 86 66 140 222 167 261 398 478 361 502 205
Accumulated Other Comprehensive Income / (Loss)		 -1.84 0.02 -1.62 1.23 -1.49 -2.07 -6.94 -3.41 -28 -22 -13

Annual Metrics And Ratios for Halozyme Therapeutics

This table displays calculated financial ratios and metrics derived from Halozyme Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 79.28% 8.61% 115.84% -52.04% 29.06% 36.53% 65.67% 48.91% 25.62% 22.44% 37.55%
EBITDA Growth		 58.28% -162.94% 237.57% -169.84% 7.17% 397.02% 70.24% 14.43% 34.41% 48.49% -10.76%
EBIT Growth		 57.12% -202.94% 202.09% -173.87% 1.83% 346.90% 85.06% -3.04% 31.77% 62.54% -14.73%
NOPAT Growth		 56.45% -203.11% 242.14% -158.62% 2.48% 404.29% 210.45% -51.41% 25.62% 61.08% -27.58%
Net Income Growth		 52.86% -219.64% 161.12% -227.57% 10.07% 278.69% 211.97% -49.81% 39.31% 57.71% -28.64%
EPS Growth		 55.36% -224.00% 155.56% -224.44% 10.71% 282.00% 201.10% -47.45% 45.83% 63.33% -25.36%
Operating Cash Flow Growth		 21.96% -35.87% 366.07% -136.93% -72.57% 164.92% 439.98% -19.81% 61.83% 23.29% 36.01%
Free Cash Flow Firm Growth		 -16.13% -9.96% 327.63% -206.08% 21.99% 136.96% 699.77% -359.01% 144.35% 22.06% -209.94%
Invested Capital Growth		 64.36% -33.32% -176.45% 134.31% 258.63% 147.64% 84.80% 295.12% -4.99% 2.12% 60.66%
Revenue Q/Q Growth		 19.30% -8.27% 90.67% -45.99% -3.24% 34.09% -4.25% 13.69% 6.22% 7.17% 12.37%
EBITDA Q/Q Growth		 26.26% -28.79% 282.08% -195.44% -114.45% 196.37% -7.65% 8.30% 10.56% 13.21% -31.22%
EBIT Q/Q Growth		 26.49% -51.48% 227.38% -197.54% -116.91% 268.07% -7.18% 7.40% 9.61% 15.31% -35.78%
NOPAT Q/Q Growth		 25.34% -50.82% 275.21% -181.68% -89.81% 317.93% -1.77% -3.99% 9.86% 12.73% -45.92%
Net Income Q/Q Growth		 22.93% -44.45% 171.32% -275.86% -80.74% 499.73% -1.56% -4.29% 10.90% 13.15% -46.79%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -409.09% -78.57% 468.75% -2.14% -2.70% 12.30% 13.95% -46.11%
Operating Cash Flow Q/Q Growth		 -62.47% -1.14% 483.41% -153.06% -76.73% 351.03% 11.80% -0.03% 5.40% 18.89% 6.64%
Free Cash Flow Firm Q/Q Growth		 -70.05% 11.66% 496.01% -127,533.84% -34.15% 191.52% 13.50% 0.65% 5.68% 13.83% -180.16%
Invested Capital Q/Q Growth		 62.45% 0.03% -54.51% -5.12% 2.67% 23.62% -2.57% -1.71% -1.30% -1.32% 55.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 78.35% 77.36% 90.16% 93.33% 76.76% 83.79% 81.64% 78.90% 76.80% 84.30% 83.62%
EBITDA Margin		 -17.85% -43.22% 27.55% -40.11% -28.85% 62.76% 64.49% 49.56% 53.03% 64.31% 41.73%
Operating Margin		 -20.33% -56.72% 25.58% -45.65% -34.50% 53.91% 62.24% 40.53% 40.71% 54.32% 33.58%
EBIT Margin		 -20.01% -55.82% 26.40% -40.66% -30.93% 55.94% 62.49% 40.69% 42.68% 56.65% 35.12%
Profit (Net Income) Margin		 -23.86% -70.23% 19.89% -52.90% -36.86% 48.24% 90.84% 30.62% 33.96% 43.74% 22.69%
Tax Burden Percent		 100.00% 101.14% 102.21% 100.67% 99.98% 99.83% 162.04% 81.20% 80.84% 79.71% 67.87%
Interest Burden Percent		 119.24% 124.40% 73.70% 129.22% 119.18% 86.39% 89.72% 92.68% 98.43% 96.85% 95.19%
Effective Tax Rate		 0.00% 0.00% -2.21% 0.00% 0.00% 0.17% -62.04% 18.80% 19.16% 20.29% 32.13%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -101.96% 114.14% 174.65% 26.42% 21.32% 34.88% 19.18%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -81.86% -198.82% 120.53% 24.05% 22.08% 35.31% 19.08%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 59.55% -7.81% 56.79% 83.81% 200.75% 163.54% 134.41%
Return on Equity (ROE)		 -76.42% -1,958.98% 71.60% -35.14% -42.41% 106.33% 231.44% 110.23% 222.07% 198.42% 153.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -631.24% -214.75% 29.20% 115.10% -92.80% 26.44% 32.78% -27.36%
Operating Return on Assets (OROA)		 -15.54% -36.94% 21.39% -12.86% -12.05% 26.13% 32.89% 18.23% 19.80% 30.30% 21.38%
Return on Assets (ROA)		 -18.54% -46.48% 16.12% -16.73% -14.36% 22.53% 47.82% 13.72% 15.75% 23.39% 13.81%
Return on Common Equity (ROCE)		 -76.42% -1,958.98% 71.60% -35.14% -42.41% 106.33% 231.44% 110.23% 222.07% 198.42% 153.59%
Return on Equity Simple (ROE_SIMPLE)		 -74.96% 317.18% 30.22% -32.28% -78.72% 85.46% 204.47% 119.04% 336.00% 122.06% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -58 83 -49 -47 144 447 217 273 440 318
NOPAT Margin		 -14.23% -39.71% 26.15% -31.96% -24.15% 53.82% 100.85% 32.91% 32.91% 43.29% 22.79%
Net Nonoperating Expense Percent (NNEP)		 -17.92% -187.09% -15.47% -12.82% -20.11% 312.95% 54.13% 2.37% -0.75% -0.44% 0.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 12.96% 17.24% 23.51% 14.53%
Cost of Revenue to Revenue		 21.65% 22.64% 9.84% 6.67% 23.24% 16.21% 18.36% 21.10% 23.20% 15.70% 16.38%
SG&A Expenses to Revenue		 29.64% 31.26% 17.00% 40.04% 39.42% 17.09% 11.35% 21.74% 17.99% 15.20% 14.83%
R&D to Revenue		 69.03% 102.83% 47.58% 98.94% 71.84% 12.79% 8.05% 10.09% 9.21% 7.79% 26.23%
Operating Expenses to Revenue		 98.67% 134.09% 64.58% 138.98% 111.26% 29.89% 19.40% 38.37% 36.09% 29.98% 50.04%
Earnings before Interest and Taxes (EBIT)		 -27 -82 84 -62 -61 150 277 269 354 575 490
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -63 87 -61 -57 168 286 327 440 653 583
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 51.59 0.00 13.84 8.50 28.31 38.22 28.74 45.31 58.26 16.72 162.13
Price to Tangible Book Value (P/TBV)		 51.59 0.00 13.84 8.50 28.31 38.22 28.74 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 16.43 8.72 9.11 13.93 13.26 21.58 12.77 11.66 5.89 5.99 5.67
Price to Earnings (P/E)		 0.00 0.00 45.80 0.00 0.00 44.73 14.06 38.06 17.34 13.70 24.97
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 2.18% 0.00% 0.00% 2.24% 7.11% 2.63% 5.77% 7.30% 4.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 93.21 35.53 32.28 17.45 6.73 4.85 5.49 4.85
Enterprise Value to Revenue (EV/Rev)		 15.99 8.80 8.27 12.42 13.16 21.69 13.08 13.39 7.29 6.89 7.10
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 30.01 0.00 0.00 34.55 20.28 27.01 13.75 10.71 17.01
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 31.31 0.00 0.00 38.77 20.93 32.90 17.08 12.16 20.21
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 31.61 0.00 0.00 40.29 12.97 40.68 22.15 15.91 31.14
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 19.52 0.00 0.00 104.64 19.36 36.80 15.56 14.60 15.22
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 21.73 0.00 0.00 157.51 19.67 0.00 17.86 16.93 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.16 -6.67 0.97 0.51 4.39 2.63 4.45 8.87 17.89 4.14 43.89
Long-Term Debt to Equity		 0.65 -6.13 0.60 0.14 4.17 0.00 4.00 8.79 17.89 4.14 43.89
Financial Leverage		 -1.72 -4.55 -1.46 -1.08 -0.73 0.04 0.47 3.48 9.09 4.63 7.04
Leverage Ratio		 4.12 42.15 4.44 2.10 2.95 4.72 4.84 8.03 14.10 8.48 11.12
Compound Leverage Factor		 4.92 52.43 3.27 2.71 3.52 4.08 4.34 7.44 13.87 8.22 10.59
Debt to Total Capital		 53.68% 117.64% 49.27% 33.68% 81.44% 72.45% 81.66% 89.87% 94.71% 80.54% 97.77%
Short-Term Debt to Total Capital		 23.55% 9.45% 18.80% 24.38% 3.95% 72.45% 8.33% 0.80% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 30.13% 108.19% 30.47% 9.29% 77.48% 0.00% 73.33% 89.07% 94.71% 80.54% 97.77%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 46.32% -17.64% 50.73% 66.32% 18.56% 27.55% 18.34% 10.13% 5.29% 19.46% 2.23%
Debt to EBITDA		 -2.07 -3.42 2.32 -2.07 -7.12 2.37 3.07 4.60 3.41 2.31 3.68
Net Debt to EBITDA		 2.43 -0.18 -3.06 3.75 0.33 0.17 0.47 3.49 2.65 1.39 3.43
Long-Term Debt to EBITDA		 -1.16 -3.14 1.43 -0.57 -6.77 0.00 2.75 4.56 3.41 2.31 3.68
Debt to NOPAT		 -2.59 -3.72 2.44 -2.60 -8.51 2.76 1.96 6.93 5.49 3.43 6.73
Net Debt to NOPAT		 3.04 -0.20 -3.22 4.70 0.39 0.20 0.30 5.26 4.26 2.07 6.28
Long-Term Debt to NOPAT		 -1.46 -3.42 1.51 -0.72 -8.09 0.00 1.76 6.87 5.49 3.43 6.73
Altman Z-Score		 6.85 -0.07 6.16 5.58 2.76 8.52 5.78 4.11 3.44 4.35 3.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.75 4.70 3.89 2.86 6.35 1.32 7.91 5.65 6.64 7.80 4.66
Quick Ratio		 2.25 4.04 3.74 2.57 5.61 1.11 7.10 4.54 5.07 6.50 3.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -48 -53 120 -128 -100 37 295 -763 338 413 -454
Operating Cash Flow to CapEx		 -1,571.31% -1,606.09% 8,710.40% -1,061.55% -2,114.43% 3,883.33% 20,551.82% 0.00% 2,540.68% 4,478.91% 9,348.03%
Free Cash Flow to Firm to Interest Expense		 -9.25 -2.65 5.48 -7.08 -8.57 1.81 10.34 -38.82 18.04 22.83 -19.24
Operating Cash Flow to Interest Expense		 -7.13 -2.52 6.10 -2.74 -7.35 2.72 10.51 12.21 20.71 26.47 27.60
Operating Cash Flow Less CapEx to Interest Expense		 -7.58 -2.68 6.03 -3.00 -7.69 2.65 10.46 13.29 19.90 25.88 27.31
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.78 0.66 0.81 0.32 0.39 0.47 0.53 0.45 0.46 0.53 0.61
Accounts Receivable Turnover		 6.50 6.10 16.75 5.83 4.38 3.41 4.70 4.10 3.56 3.74 3.73
Inventory Turnover		 3.68 2.75 3.15 0.73 1.75 0.96 1.42 1.81 1.69 1.18 1.44
Fixed Asset Turnover		 39.18 35.75 81.35 27.65 21.40 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 7.80 8.22 5.41 1.69 8.66 10.37 46.94 14.49 13.04 14.45 14.69
Days Sales Outstanding (DSO)		 56.16 59.83 21.80 62.66 83.29 107.19 77.69 89.04 102.40 97.54 97.97
Days Inventory Outstanding (DIO)		 99.19 132.52 115.81 500.02 208.30 379.19 257.02 201.79 216.05 308.48 253.95
Days Payable Outstanding (DPO)		 46.82 44.39 67.52 216.55 42.12 35.19 7.78 25.20 28.00 25.26 24.85
Cash Conversion Cycle (CCC)		 108.53 147.96 70.09 346.13 249.46 451.19 326.93 265.63 290.45 380.76 327.07
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -16 -21 -59 20 73 180 332 1,313 1,247 1,274 2,046
Invested Capital Turnover		 -4.43 -7.86 -7.88 -7.84 4.22 2.12 1.73 0.80 0.65 0.81 0.84
Increase / (Decrease) in Invested Capital		 29 -5.33 -38 79 52 107 152 980 -66 26 772
Enterprise Value (EV)		 2,160 1,291 2,617 1,887 2,579 5,803 5,797 8,837 6,046 6,992 9,914
Market Capitalization		 2,218 1,279 2,884 2,115 2,598 5,774 5,661 7,694 4,882 6,083 7,914
Book Value per Share		 $0.34 ($0.25) $1.46 $1.72 $0.63 $1.12 $1.40 $1.26 $0.63 $2.86 $0.42
Tangible Book Value per Share		 $0.34 ($0.25) $1.46 $1.72 $0.63 $1.12 $1.40 ($5.81) ($6.10) ($3.57) ($12.87)
Total Capital		 93 184 411 375 494 548 1,074 1,676 1,583 1,870 2,191
Total Debt		 50 217 202 126 403 397 877 1,506 1,499 1,506 2,143
Total Long-Term Debt		 28 199 125 35 383 0.00 787 1,493 1,499 1,506 2,143
Net Debt		 -59 12 -267 -228 -19 29 136 1,143 1,163 910 2,000
Capital Expenditures (CapEx)		 2.36 3.14 1.54 4.66 4.04 1.43 1.46 -21 15 11 6.97
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 23 14 -13 15 56 163 158 259 298 350 505
Debt-free Net Working Capital (DFNWC)		 131 219 456 370 477 531 899 622 634 946 648
Net Working Capital (NWC)		 109 202 379 278 458 133 809 608 634 946 648
Net Nonoperating Expense (NNE)		 13 45 20 32 25 15 44 15 -8.69 -4.51 1.45
Net Nonoperating Obligations (NNO)		 -59 11 -267 -229 -19 29 135 1,143 1,163 910 1,997
Total Depreciation and Amortization (D&A)		 2.92 18 3.62 0.84 4.08 18 8.90 59 86 78 92
Debt-free, Cash-free Net Working Capital to Revenue		 16.91% 9.79% -4.09% 10.19% 28.61% 60.76% 35.56% 39.20% 35.93% 34.49% 36.18%
Debt-free Net Working Capital to Revenue		 97.13% 149.53% 144.10% 243.64% 243.55% 198.29% 202.69% 94.16% 76.45% 93.20% 46.41%
Net Working Capital to Revenue		 80.94% 137.67% 119.72% 183.38% 233.58% 49.84% 182.52% 92.14% 76.45% 93.20% 46.41%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.25) ($0.81) $0.46 ($0.56) $0.00 $0.95 $2.86 $1.48 $2.13 $3.50 $2.64
Adjusted Weighted Average Basic Shares Outstanding		 129.06M 129.76M 136.42M 143.60M 144.33M 136.21M 140.65M 136.84M 131.93M 126.83M 119.84M
Adjusted Diluted Earnings per Share		 ($0.25) ($0.81) $0.45 ($0.56) ($0.50) $0.91 $2.74 $1.44 $2.10 $3.43 $2.56
Adjusted Weighted Average Diluted Shares Outstanding		 129.06M 129.76M 139.07M 143.60M 144.33M 141.46M 146.80M 140.61M 134.20M 129.42M 123.90M
Adjusted Basic & Diluted Earnings per Share		 ($0.25) ($0.81) $0.00 $0.00 ($0.50) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 126.70M 127.96M 143.08M 145.03M 144.33M 135.28M 137.70M 135.37M 126.82M 123.15M 118.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -58 57 -49 -47 144 193 217 273 440 351
Normalized NOPAT Margin		 -14.23% -39.71% 17.91% -31.96% -24.15% 53.82% 43.57% 32.91% 32.91% 43.29% 25.16%
Pre Tax Income Margin		 -23.86% -69.44% 19.46% -52.54% -36.86% 48.32% 56.06% 37.71% 42.01% 54.87% 33.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.20 -4.10 3.80 -3.42 -5.21 7.35 9.72 13.66 18.86 31.79 20.78
NOPAT to Interest Expense		 -3.69 -2.92 3.77 -2.69 -4.07 7.07 15.69 11.05 14.55 24.29 13.49
EBIT Less CapEx to Interest Expense		 -5.65 -4.26 3.73 -3.68 -5.56 7.28 9.67 14.74 18.05 31.20 20.49
NOPAT Less CapEx to Interest Expense		 -4.15 -3.07 3.70 -2.95 -4.42 7.00 15.64 12.13 13.73 23.70 13.19
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -276.85% 116.29% 86.93% 98.95% 142.89% 56.29% 108.04%

Quarterly Metrics And Ratios for Halozyme Therapeutics

This table displays calculated financial ratios and metrics derived from Halozyme Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 118,017,000.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 118,017,000.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 1.27
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3.38% 26.75% 20.81% 4.67% 34.28% 29.55% 35.22% 40.79% 22.12% 51.60% 42.23%
EBITDA Growth		 -0.65% 49.75% 53.80% 19.15% 62.05% 60.26% 40.54% 63.05% 29.89% -130.56% 31.28%
EBIT Growth		 10.88% 41.18% 77.06% 25.21% 82.31% 71.77% 47.56% 71.21% 31.58% -149.50% 25.27%
NOPAT Growth		 1.93% 40.40% 87.33% 22.49% 90.71% 58.23% 52.04% 75.72% 28.81% -148.19% 32.12%
Net Income Growth		 32.78% 47.98% 93.92% 24.74% 67.42% 60.46% 53.72% 77.12% 27.89% -203.34% 27.06%
EPS Growth		 38.64% 56.10% 106.90% 28.57% 72.13% 65.63% 55.00% 84.72% 36.19% -206.60% 31.18%
Operating Cash Flow Growth		 90.15% 24.14% 48.83% -16.53% -12.87% 74.36% 19.16% 78.71% 54.80% 22.73% 16.77%
Free Cash Flow Firm Growth		 115.45% 116.40% 116.29% 20.80% -24.14% -28.10% -38.31% 2.87% 40.49% -872.34% -822.85%
Invested Capital Growth		 -5.38% -4.99% -5.36% -2.76% 2.14% 2.12% 2.19% 2.44% 1.72% 60.66% 64.55%
Revenue Q/Q Growth		 -2.26% 6.48% -14.85% 18.11% 25.39% 2.73% -11.12% 22.98% 8.76% 27.52% -16.61%
EBITDA Q/Q Growth		 -1.85% 8.54% -4.92% 17.63% 33.49% 7.35% -16.62% 36.47% 6.34% -125.26% 458.14%
EBIT Q/Q Growth		 -4.70% 14.32% -5.51% 21.62% 38.77% 7.71% -18.82% 41.10% 6.65% -140.52% 305.43%
NOPAT Q/Q Growth		 -6.34% 20.11% -10.36% 21.47% 45.83% -0.34% -13.87% 40.39% 6.89% -137.29% 336.12%
Net Income Q/Q Growth		 9.48% 4.34% -10.03% 21.38% 46.94% 0.00% -13.81% 39.85% 6.09% -180.81% 205.97%
EPS Q/Q Growth		 8.93% 4.92% -6.25% 20.00% 45.83% 0.95% -12.26% 43.01% 7.52% -179.02% 207.96%
Operating Cash Flow Q/Q Growth		 98.10% -22.70% 26.45% -56.89% 106.79% 54.68% -13.59% -35.35% 79.11% 22.64% -17.78%
Free Cash Flow Firm Q/Q Growth		 34.10% 5.58% -3.65% -11.44% -15.80% 0.07% -17.32% 47.66% 15.00% -650.13% 22.62%
Invested Capital Q/Q Growth		 -2.71% -1.30% -2.55% 3.92% 2.19% -1.32% -2.49% 4.18% 1.47% 55.86% -0.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 74.62% 77.27% 85.54% 82.88% 82.96% 85.89% 81.73% 85.77% 84.41% 82.56% 78.97%
EBITDA Margin		 53.92% 54.96% 61.37% 61.12% 65.07% 67.99% 63.78% 70.78% 69.21% -13.71% 58.87%
Operating Margin		 40.86% 43.92% 48.78% 50.67% 56.26% 58.89% 53.44% 62.15% 61.51% -20.56% 48.98%
EBIT Margin		 43.08% 46.25% 51.33% 52.85% 58.49% 61.33% 56.01% 64.27% 63.02% -20.02% 49.33%
Profit (Net Income) Margin		 37.88% 37.12% 39.22% 40.30% 47.23% 45.98% 44.59% 50.71% 49.46% -31.34% 39.83%
Tax Burden Percent		 80.42% 84.40% 80.00% 79.19% 82.96% 76.88% 82.11% 80.59% 80.03% 140.40% 83.21%
Interest Burden Percent		 109.34% 95.09% 95.52% 96.30% 97.33% 97.52% 96.95% 97.90% 98.08% 111.48% 97.04%
Effective Tax Rate		 19.58% 15.60% 20.00% 20.81% 17.04% 23.12% 17.89% 19.41% 19.97% 0.00% 16.79%
Return on Invested Capital (ROIC)		 19.74% 24.02% 26.95% 27.36% 34.62% 36.48% 38.73% 46.19% 47.00% -12.11% 37.43%
ROIC Less NNEP Spread (ROIC-NNEP)		 20.71% 24.03% 26.98% 27.40% 34.80% 36.68% 38.94% 46.39% 47.11% -17.38% 37.16%
Return on Net Nonoperating Assets (RNNOA)		 134.75% 218.49% 249.78% 131.96% 91.83% 169.85% 106.00% 144.24% 81.08% -122.43% 136.76%
Return on Equity (ROE)		 154.49% 242.50% 276.73% 159.32% 126.46% 206.32% 144.72% 190.43% 128.09% -134.54% 174.19%
Cash Return on Invested Capital (CROIC)		 24.65% 26.44% 30.19% 28.21% 28.42% 32.78% 36.86% 40.59% 43.52% -27.36% -27.20%
Operating Return on Assets (OROA)		 17.90% 21.46% 25.02% 24.42% 27.63% 32.80% 30.08% 37.66% 36.10% -12.19% 30.57%
Return on Assets (ROA)		 15.74% 17.22% 19.12% 18.62% 22.31% 24.59% 23.95% 29.71% 28.33% -19.08% 24.68%
Return on Common Equity (ROCE)		 154.49% 242.50% 276.73% 159.32% 126.46% 206.32% 144.72% 190.43% 128.09% -134.54% 174.19%
Return on Equity Simple (ROE_SIMPLE)		 101.90% 0.00% 179.30% 116.54% 86.69% 0.00% 100.64% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 71 85 76 93 135 135 116 163 174 -65 154
NOPAT Margin		 32.86% 37.07% 39.02% 40.13% 46.67% 45.28% 43.88% 50.09% 49.23% -14.39% 40.76%
Net Nonoperating Expense Percent (NNEP)		 -0.96% -0.01% -0.03% -0.04% -0.17% -0.20% -0.21% -0.21% -0.10% 5.27% 0.27%
Return On Investment Capital (ROIC_SIMPLE)		 - 5.39% - - - 7.22% 5.84% 8.86% 8.66% -2.97% 6.49%
Cost of Revenue to Revenue		 25.38% 22.73% 14.46% 17.12% 17.04% 14.11% 18.27% 14.23% 15.59% 17.44% 21.03%
SG&A Expenses to Revenue		 16.33% 16.35% 17.94% 15.44% 14.22% 14.18% 15.99% 12.78% 13.01% 17.05% 15.37%
R&D to Revenue		 8.02% 9.27% 9.76% 9.09% 6.36% 6.86% 5.59% 5.39% 4.87% 70.12% 6.79%
Operating Expenses to Revenue		 33.76% 33.34% 36.76% 32.21% 26.70% 27.00% 28.29% 23.62% 22.89% 103.13% 29.98%
Earnings before Interest and Taxes (EBIT)		 93 106 101 122 170 183 148 209 223 -90 186
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 116 126 120 141 189 203 169 231 245 -62 222
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 20.22 58.26 30.22 23.03 16.02 16.72 16.29 19.26 17.02 162.13 34.73
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 6.45 5.89 6.23 7.63 7.65 5.99 7.25 5.44 6.90 5.67 5.06
Price to Earnings (P/E)		 19.85 17.34 16.86 19.76 18.48 13.70 16.19 11.50 14.41 24.97 21.87
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 5.04% 5.77% 5.93% 5.06% 5.41% 7.30% 6.18% 8.69% 6.94% 4.00% 4.57%
Enterprise Value to Invested Capital (EV/IC)		 4.79 4.85 5.28 6.05 6.27 5.49 6.94 5.70 7.15 4.85 4.63
Enterprise Value to Revenue (EV/Rev)		 7.75 7.29 7.43 8.75 8.54 6.89 7.95 6.25 7.55 7.10 6.27
Enterprise Value to EBITDA (EV/EBITDA)		 15.22 13.75 13.31 15.14 14.02 10.71 12.28 9.32 11.08 17.01 14.87
Enterprise Value to EBIT (EV/EBIT)		 18.75 17.08 16.12 18.09 16.21 12.16 13.83 10.38 12.29 20.21 17.91
Enterprise Value to NOPAT (EV/NOPAT)		 24.37 22.15 20.79 23.47 20.74 15.91 17.98 13.41 15.95 31.14 26.64
Enterprise Value to Operating Cash Flow (EV/OCF)		 16.42 15.56 14.87 18.19 20.07 14.60 17.10 13.46 15.36 15.22 13.96
Enterprise Value to Free Cash Flow (EV/FCFF)		 18.90 17.86 16.99 21.14 22.29 16.93 19.03 14.20 16.57 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 6.01 17.89 8.44 5.19 3.32 4.14 3.13 4.54 3.00 43.89 9.76
Long-Term Debt to Equity		 6.01 17.89 8.44 5.19 3.32 4.14 3.13 4.54 1.59 43.89 8.81
Financial Leverage		 6.51 9.09 9.26 4.82 2.64 4.63 2.72 3.11 1.72 7.04 3.68
Leverage Ratio		 10.85 14.10 14.53 8.58 5.71 8.48 6.12 6.47 4.54 11.12 6.94
Compound Leverage Factor		 11.87 13.40 13.88 8.26 5.56 8.27 5.93 6.33 4.45 12.40 6.73
Debt to Total Capital		 85.74% 94.71% 89.41% 83.85% 76.87% 80.54% 75.76% 81.93% 74.99% 97.77% 90.71%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 35.28% 0.00% 8.83%
Long-Term Debt to Total Capital		 85.74% 94.71% 89.41% 83.85% 76.87% 80.54% 75.76% 81.93% 39.71% 97.77% 81.88%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 14.27% 5.29% 10.59% 16.15% 23.13% 19.46% 24.24% 18.07% 25.01% 2.23% 9.29%
Debt to EBITDA		 3.77 3.41 3.12 2.98 2.61 2.31 2.15 1.91 1.78 3.68 3.37
Net Debt to EBITDA		 2.55 2.65 2.15 1.93 1.45 1.39 1.08 1.22 0.95 3.43 2.87
Long-Term Debt to EBITDA		 3.77 3.41 3.12 2.98 2.61 2.31 2.15 1.91 0.94 3.68 3.05
Debt to NOPAT		 6.03 5.49 4.87 4.62 3.86 3.43 3.14 2.75 2.57 6.73 6.04
Net Debt to NOPAT		 4.08 4.26 3.36 2.99 2.15 2.07 1.58 1.75 1.37 6.28 5.15
Long-Term Debt to NOPAT		 6.03 5.49 4.87 4.62 3.86 3.43 3.14 2.75 1.36 6.73 5.46
Altman Z-Score		 3.06 2.97 3.20 3.73 4.16 3.73 4.38 3.97 4.47 2.69 3.05
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.63 6.64 6.64 7.41 10.36 7.80 8.39 8.36 1.59 4.66 2.76
Quick Ratio		 6.08 5.07 5.01 5.58 8.75 6.50 7.00 6.44 1.25 3.30 2.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 143 151 145 129 108 108 90 132 152 -838 -648
Operating Cash Flow to CapEx		 4,497.66% 3,942.76% 3,650.97% 2,160.88% 7,605.54% 5,847.54% 16,233.79% 6,379.46% 5,894.29% 15,348.91% 4,813.63%
Free Cash Flow to Firm to Interest Expense		 31.71 28.89 32.24 28.45 23.95 23.88 19.81 30.13 35.44 -80.62 -117.66
Operating Cash Flow to Interest Expense		 29.39 19.61 28.72 12.33 25.50 39.31 34.08 22.69 41.57 21.08 32.69
Operating Cash Flow Less CapEx to Interest Expense		 28.74 19.11 27.93 11.76 25.17 38.64 33.87 22.34 40.87 20.95 32.01
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.42 0.46 0.49 0.46 0.47 0.53 0.54 0.59 0.57 0.61 0.62
Accounts Receivable Turnover		 3.47 3.56 4.42 3.79 3.77 3.74 4.33 4.44 3.93 3.73 3.96
Inventory Turnover		 1.57 1.69 1.34 1.20 1.30 1.18 1.08 1.09 1.21 1.44 1.62
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 14.37 0.00 0.00 0.00 19.46
Accounts Payable Turnover		 9.72 13.04 16.85 13.70 10.70 14.45 10.75 10.92 13.84 14.69 15.19
Days Sales Outstanding (DSO)		 105.34 102.40 82.64 96.28 96.91 97.54 84.24 82.20 92.77 97.97 92.26
Days Inventory Outstanding (DIO)		 232.60 216.05 271.57 304.12 280.04 308.48 339.00 333.97 301.42 253.95 225.19
Days Payable Outstanding (DPO)		 37.55 28.00 21.66 26.64 34.12 25.26 33.96 33.44 26.38 24.85 24.02
Cash Conversion Cycle (CCC)		 300.39 290.45 332.55 373.76 342.83 380.76 389.28 382.73 367.81 327.07 293.43
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1,264 1,247 1,215 1,263 1,291 1,274 1,242 1,294 1,313 2,046 2,043
Invested Capital Turnover		 0.60 0.65 0.69 0.68 0.74 0.81 0.88 0.92 0.95 0.84 0.92
Increase / (Decrease) in Invested Capital		 -72 -66 -69 -36 27 26 27 31 22 772 802
Enterprise Value (EV)		 6,054 6,046 6,411 7,638 8,089 6,992 8,618 7,371 9,387 9,914 9,453
Market Capitalization		 5,039 4,882 5,374 6,664 7,251 6,083 7,858 6,410 8,578 7,914 7,627
Book Value per Share		 $1.89 $0.63 $1.40 $2.27 $3.57 $2.86 $3.92 $2.70 $4.31 $0.42 $1.86
Tangible Book Value per Share		 ($4.99) ($6.10) ($5.47) ($4.44) ($3.03) ($3.57) ($2.59) ($3.66) ($2.24) ($12.87) ($11.14)
Total Capital		 1,747 1,583 1,679 1,792 1,957 1,870 1,990 1,842 2,015 2,191 2,364
Total Debt		 1,498 1,499 1,501 1,503 1,504 1,506 1,507 1,509 1,511 2,143 2,145
Total Long-Term Debt		 1,498 1,499 1,501 1,503 1,504 1,506 1,507 1,509 800 2,143 1,936
Net Debt		 1,014 1,163 1,037 973 838 910 760 961 809 2,000 1,826
Capital Expenditures (CapEx)		 2.94 2.60 3.55 2.58 1.52 3.05 0.95 1.56 3.03 1.43 3.74
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 281 298 278 325 352 350 364 440 500 505 530
Debt-free Net Working Capital (DFNWC)		 764 634 742 854 1,018 946 1,112 988 1,202 648 849
Net Working Capital (NWC)		 764 634 742 854 1,018 946 1,112 988 492 648 640
Net Nonoperating Expense (NNE)		 -11 -0.12 -0.39 -0.40 -1.62 -2.09 -1.88 -2.01 -0.83 77 3.49
Net Nonoperating Obligations (NNO)		 1,014 1,163 1,037 973 838 910 760 961 809 1,997 1,824
Total Depreciation and Amortization (D&A)		 23 20 20 19 19 20 21 21 22 29 36
Debt-free, Cash-free Net Working Capital to Revenue		 35.93% 35.93% 32.27% 37.26% 37.14% 34.49% 33.54% 37.35% 40.25% 36.18% 35.13%
Debt-free Net Working Capital to Revenue		 97.84% 76.45% 85.97% 97.84% 107.47% 93.20% 102.52% 83.86% 96.73% 46.41% 56.25%
Net Working Capital to Revenue		 97.84% 76.45% 85.97% 97.84% 107.47% 93.20% 102.52% 83.86% 39.55% 46.41% 42.42%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.62 $0.65 $0.61 $0.73 $1.08 $1.08 $0.96 $1.36 $1.49 ($1.17) $1.27
Adjusted Weighted Average Basic Shares Outstanding		 131.97M 131.93M 126.94M 127.12M 126.85M 126.83M 123.22M 121.34M 117.22M 119.84M 118.14M
Adjusted Diluted Earnings per Share		 $0.61 $0.64 $0.60 $0.72 $1.05 $1.06 $0.93 $1.33 $1.43 ($1.13) $1.22
Adjusted Weighted Average Diluted Shares Outstanding		 134.08M 134.20M 128.89M 129.22M 130.13M 129.42M 126.64M 124.16M 122.33M 123.90M 122.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 132.10M 126.82M 127.27M 126.68M 127.23M 123.15M 123.22M 116.97M 117.60M 118.02M 118.61M
Normalized Net Operating Profit after Tax (NOPAT)		 71 85 76 93 135 135 116 163 174 -65 154
Normalized NOPAT Margin		 32.86% 37.07% 39.02% 40.13% 46.67% 45.28% 43.88% 50.09% 49.23% -14.39% 40.76%
Pre Tax Income Margin		 47.10% 43.98% 49.02% 50.89% 56.93% 59.80% 54.30% 62.92% 61.81% -22.32% 47.87%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 20.66 20.38 22.31 27.03 37.50 40.25 32.79 47.64 51.97 -8.71 33.74
NOPAT to Interest Expense		 15.76 16.34 16.96 20.52 29.93 29.72 25.68 37.13 40.59 -6.26 27.88
EBIT Less CapEx to Interest Expense		 20.00 19.88 21.52 26.46 37.17 39.58 32.58 47.28 51.26 -8.85 33.06
NOPAT Less CapEx to Interest Expense		 15.11 15.84 16.17 19.95 29.59 29.05 25.47 36.77 39.89 -6.40 27.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 59.11% 142.89% 79.14% 74.80% 64.29% 56.29% 0.00% 99.32% 99.48% 108.04% 0.00%

Financials Breakdown Chart

Key Financial Trends

Halozyme Therapeutics (HALO) has delivered a generally favorable trajectory across revenue, gross margins, and operating cash flow from 2022 through 2025, with notable strength in 2024 and 2025 up to the third quarter. The company demonstrates solid gross profitability and improving liquidity, but faces a one-off profitability challenge in Q4 2025 alongside a sizable investment-related cash outflow and an elevated debt load. The following concise points summarize the most relevant trends a retail investor may want to consider when evaluating HALO’s recent four-year performance.

  • Revenue growth in 2025: Halozyme’s quarterly operating revenue rose through 2025, increasing from about $264.9 million in Q1 2025 to $451.8 million in Q4 2025, signaling strong top-line momentum heading into 2026. (Q1 2025: 264,861,000; Q4 2025: 451,767,000)
  • Stable, high gross margins: Total gross profit consistently remained in the 80%+ range, with Q4 2025 gross profit of about $373.0 million on $451.8 million revenue (roughly 83%), indicating solid core profitability.
  • Strong operating cash flow in 2025 quarters: Net cash from continuing operating activities was positive in every 2025 quarter, including Q1 (~$154.2M), Q2 (~$99.7M), Q3 (~$178.6M), and Q4 (~$219.0M), underscoring healthy cash generation from core operations.
  • Investing cash inflows in late 2025: Halozyme benefited from investments activity, with sale/maturity of investments contributing about $209.6 million in Q3 2025 and $273.4 million in Q4 2025, boosting overall liquidity.
  • Earnings per share on the rise in mid-2025: Diluted EPS reached about $1.43 in Q3 2025, higher than the $1.33 reported in Q3 2024, indicating improving quarterly profitability at that point in time.
  • Equity base expanding: Total equity grew to roughly $503.9 million by Q3 2025, up from about $333 million in Q2 2025, signaling ongoing capital formation and positive book value development.
  • Total assets trending higher: Total assets rose to about $2.22 billion by Q3 2025, up from roughly $2.06 billion in Q2 2025, reflecting asset growth alongside rising liquidity and scale.
  • Liquidity context improving, with solid current assets: As of Q3 2025, Total current assets were about $1.329 billion against Total current liabilities of about $837 million, suggesting a reasonable current ratio and liquidity cushion.
  • Leverage remains meaningful but common for biotech-capital structures: Long-term debt around $1.50 billion in 2025 Q3 indicates a high yet typical leverage level for pharma/biotech companies with large upfront R&D and collaboration-based revenues.
  • Non-cash items and one-off effects in Q4 2025: Large non-cash adjustments to net income in Q4 2025 (about $358.3 million) highlight significant one-off accounting effects that are not cash-based and may affect reported earnings versus cash flow impressions.

Bottom-line takeaway: Halozyme’s revenue and gross margins have been generally strong and expanding through 2025, and operating cash flow remains robust across quarters. However, the firm posted a Q4 2025 net loss and experienced a substantial investing cash outflow that quarter, alongside a sizeable debt burden. Investors should weigh the company’s ongoing ability to convert revenue growth into sustained free cash flow against the near-term earnings volatility and leverage. As with many biopharma-related businesses, the path to profitability may increasingly depend on product-line performance, collaboration revenues, and the company’s ongoing use of capital to fund R&D and strategic investments.

05/18/26 10:55 PM ETAI Generated. May Contain Errors.

Halozyme Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Halozyme Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Halozyme Therapeutics' net income appears to be on an upward trend, with a most recent value of $316.89 million in 2025, falling from -$32.23 million in 2015. The previous period was $444.09 million in 2024. See Halozyme Therapeutics' forecast for analyst expectations on what's next for the company.

Halozyme Therapeutics' total operating income in 2025 was $469.01 million, based on the following breakdown:
  • Total Gross Profit: $1.17 billion
  • Total Operating Expenses: $698.83 million

Over the last 10 years, Halozyme Therapeutics' total revenue changed from $135.06 million in 2015 to $1.40 billion in 2025, a change of 934.1%.

Halozyme Therapeutics' total liabilities were at $2.48 billion at the end of 2025, a 45.7% increase from 2024, and a 1,684.4% increase since 2015.

In the past 10 years, Halozyme Therapeutics' cash and equivalents has ranged from $43.29 million in 2015 to $234.20 million in 2022, and is currently $133.82 million as of their latest financial filing in 2025.

Over the last 10 years, Halozyme Therapeutics' book value per share changed from 0.34 in 2015 to 0.42 in 2025, a change of 23.6%.


Related Companies

Financial statements for NASDAQ:HALO last updated on 5/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Why Elon just bought a power plant (Ticker inside)
Elon Musk is burning nearly $1 billion a month because he cannot power the world's largest supercomputer witho...
Behind the Markets | Sponsoredtc pixel
The biggest IPO in history just set a date
SpaceX has targeted June 12th for its public debut, with an estimated $1.75 trillion valuation that would make...
NXT Wave Research | Sponsoredtc pixel
I had never heard of this 1888 account
An investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...
The Oxford Club | Sponsoredtc pixel
People are furious about what's happening alongside the SpaceX IPO
SpaceX is going public - but hedge fund trader Larry Benedict says the IPO is only half the story. Alongside i...
Brownstone Research | Sponsoredtc pixel
BIGGER than the SpaceX IPO?
Jon Najarian believes the SpaceX IPO - potentially arriving as soon as June 9th - may not even be the biggest ...
Banyan Hill Publishing | Sponsoredtc pixel